Biotech Business - May 25, 2021
Xbrane announces new business goals
Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum. Xbrane is on track towards regulatory submission for Xlucane (Lucentis biosimilar candidate) in EU Q3 and US Q4 2021, the company states in a press release. At the same time the […]
Biotech Business - April 20, 2021
Lipum becomes listed on Nasdaq First North
On Thursday, April 22, shares in Lipum will be traded on the Nasdaq First North Growth Market for the very first time. The company will ring Nasdaq’s opening bell, which has been specially transported to Umeå, to mark the occasion. Begin clinical trials in the spring of 2022 Lipum has developed a biological drug candidate […]
Biotech Business - April 19, 2021
Oncopeptides submits application for conditional marketing authorization of melflufen in the EU
Oncopeptides has submitted an application to the European Medicines Agency, EMA, for conditional marketing authorization of melflufen (melphalan flufenamide) in the EU, based on the phase 2 HORIZON study in relapsed refractory multiple myeloma. Pending a positive validation from the EMA, melflufen will be subject to a regulatory assessment according to the standard timelines. “Following […]
